Clinical data | |
---|---|
Other names | PEAQX, NVP-AAM077 |
Identifiers | |
| |
PubChem CID | |
ChemSpider |
|
UNII | |
Chemical and physical data | |
Formula | C17H17BrN3O5P |
Molar mass | 454.217 g·mol−1 |
3D model (JSmol) | |
| |
| |
NY (what is this?) (verify) |
PEAQX is a competitive antagonist at the NMDA receptor. Although originally described as 100-fold selective for GluN1/GluN2A receptors vs. GluN1/GluN2B receptors, more detailed studies[1] of the Ki of PEAQX revealed it only shows a 5 fold difference in affinity for GluN1/GluN2A vs. GluN1/GluN2B receptors. It is also a potent anticonvulsant in animal tests.[2]